Clinical Trial Update: Rosiglitazone in Treating Patients With Pituitary Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of rosiglitazone in patients with brain and central nervous system tumors was terminated, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain and Central Nervous System Tumors

Drugs mentioned

• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Brain and Central Nervous System Tumors | Phase 2 | Status: TERMINATED | Results posted: 2013-04-15